[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,437,268
  • Shares Outstanding, K 202,698
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,778 M
  • EBITDA $ 1,872 M
  • 60-Month Beta 0.76
  • Price/Sales 4.67
  • Price/Cash Flow 19.15
  • Price/Book 3.78

Options Overview Details

View History
  • Implied Volatility 33.53% (-1.30%)
  • Historical Volatility 38.14%
  • IV Percentile 20%
  • IV Rank 21.66%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 11) 5.24 (4.34%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 338
  • Volume Avg (30-Day) 732
  • Put/Call OI Ratio 1.56
  • Today's Open Interest 25,066
  • Open Int (30-Day) 22,287
  • Expected Range 115.32 to 125.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-3.58
  • Number of Estimates 6
  • High Estimate $-2.60
  • Low Estimate $-4.31
  • Prior Year $2.03
  • Growth Rate Est. (year over year) -276.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
110.56 +9.04%
on 07/15/26
132.60 -9.08%
on 07/28/26
+2.51 (+2.13%)
since 07/07/26
3-Month
92.18 +30.79%
on 06/02/26
132.60 -9.08%
on 07/28/26
+22.79 (+23.31%)
since 05/07/26
52-Week
77.69 +55.18%
on 08/08/25
132.60 -9.08%
on 07/28/26
+42.36 (+54.17%)
since 08/07/25

Most Recent Stories

More News
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Corporation (Nasdaq: INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company’s common stock and stock option awards...

INCY : 120.56 (+1.84%)
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds

1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds

UBSI : 48.32 (-0.54%)
GWW : 1,277.55 (-0.39%)
INCY : 120.56 (+1.84%)
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura ® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease...

INCY : 120.56 (+1.84%)
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly

Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly

INCY : 120.56 (+1.84%)
Incyte: Q2 Earnings Snapshot

Incyte: Q2 Earnings Snapshot

INCY : 120.56 (+1.84%)
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an increase of 38% and 40%, respectively, compared to the second quarter of 2025 ...

INCY : 120.56 (+1.84%)
What To Expect From Incyte’s (INCY) Q2 Earnings

What To Expect From Incyte’s (INCY) Q2 Earnings

INCY : 120.56 (+1.84%)
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Agreement provides Incyte the rights to develop and commercialize ENHANZE ® with its mutCALR development program and an option to nominate up to two additional targets

INCY : 120.56 (+1.84%)
HALO : 103.12 (+20.24%)
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational,...

INCY : 120.56 (+1.84%)
What to Expect From Incyte's Q2 2026 Earnings Report

Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.

XLV : 165.68 (+0.75%)
$SPX : 7,757.64 (+0.62%)
INCY : 120.56 (+1.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 125.33
2nd Resistance Point 123.11
1st Resistance Point 121.83
Last Price 120.56
1st Support Level 118.33
2nd Support Level 116.11
3rd Support Level 114.83

See More

52-Week High 132.60
Last Price 120.56
Fibonacci 61.8% 111.62
Fibonacci 50% 105.15
Fibonacci 38.2% 98.67
52-Week Low 77.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.